Rheumatoid arthritis (RA) is the most common inflammatory form of arthritis as well as affects approximately Two million Americans. RA is a persistent, systemic autoimmune disease that preferentially attacks the joints but additionally attacks other body organ systems such as the lung area, eyes, skin, as well as cardiovascular system.
The notion that "it's just arthritis" does not apply to RA. Many recent epidemiologic studies have demonstrated that mortality rate in RA patients is higher than in people without rheumatoid arthritis.
What is more troubling is that this increase in mortality seems to be getting worse according to a study reported in the November 07 issue of Arthritis and Rheumatism.
"We found absolutely no evidence indicating that RA subjects experienced improvements in survival during the last 4 - 5 decades," senior author Doctor. Sherine E. Gabriel from the Mayonnaise Clinic in Rochester, Minnesota, said in a news release. "In fact, RA topics did not even experience the same improvements within survival as their friends without arthritis, producing a worsening of the relative mortality in more recent years, and a widening of the mortality gap between RA subjects and the general populace throughout time.Inch
During the past few decades associated with increased survival within the population at large, sufferers with RA have also taken advantage of earlier diagnosis, more recent drug protocols, and more aggressive treatment programs. However, whether these types of improvements in management are associated with improved survival has not been well defined.
Using the permanent medical record database of all citizens of Olmsted County, Minnesota (where the Mayo Center is located), the researchers identified 822 subjects along with RA by American College of Rheumatology criteria, aged 18 years or older. This included all residents of Rochester, Minnesota, first identified as having RA between January One, 1955, and The month of january 1, 1995, as well as all residents associated with Olmsted County diagnosed with RA between January 1, 1998, and January One, 2000.
The imply age at RA beginning was 57.Six years; 71.5% of the patients were women. Follow-up ongoing until death or January 1, 2007. During follow-up of a median duration 11.Seven years, 445 patients along with RA died.
Using statistical models adjusting with regard to age and sex, the investigators in comparison the survival prices of patients identified as having RA from 1955 to 1964, 1965 to 1974, 1973 to 1984, 1985 to 1994, as well as 1995 to 2000. During these 5 time periods, survival rates for RA patients did not change significantly, indicating absolutely no significant improvement in lifespan.
Although the anticipated mortality rate in the general population fallen dramatically for both men and women between 1965 and August 2005, the mortality price for female and male RA sufferers was constant from 2.4 and 2.5 per 100 person-years, respectively, during the exact same time period. For women within the Minnesota general populace, mortality decreased from 1.0 per 100 person-years in 1965 to 0.2 per 100 person-years in 2000, whereas for men, death decreased from 1.2 per One hundred person-years in 1965 to Zero.3 per 100 person-years in 2000.
"Although the reasons for the widening mortality gap are not clear, cardiovascular deaths constitute at least half of the deaths in subjects with RA, and it is possible that the cardiovascular interventions which improved life expectancy within the general population may not have had the same beneficial effects in persons with RA," Dr. Gabriel stated.
The authors perform point out some possible flaws in their analysis. One study restriction was the fact that the study was conducted within 1 geographic area and the majority of subjects were Caucasian. Another disadvantage is that the study could not count individuals with RA that did not present for health care. Finally, it is not possible to extrapolate the findings to patients diagnosed with RA after Two thousand, who may have been treated more aggressively with biologic therapy.
The authors urgently suggest research that will clarify the reasons behind this mortality discrepancy and that will lead to solutions enhancing survival in sufferers with RA. (Arthritis Rheum. 2007;56:3583-3587).
Author's be aware: Currently, there is an huge amount of research being carried out to develop more effective, more selective, and less dangerous RA therapies. Whether these therapies will have a substantial impact on mortality continues to be unsure. There is interesting evidence that TNF inhibitors may possibly reduce the rate of atherosclerotic disease in RA. And there is also some evidence that these drugs might reduce the incidence associated with lymphoma in patients along with RA. This is counterbalanced by the rise in respiratory infections that occur in patients given TNF inhibitors. Only time and more research will give all of us the answers.
Article Source: articlemotron . com
No comments:
Post a Comment